PMID- 25864425
OWN - NLM
STAT- MEDLINE
DCOM- 20160303
LR  - 20181211
IS  - 1873-5177 (Electronic)
IS  - 0091-3057 (Linking)
VI  - 133
DP  - 2015 Jun
TI  - Antidepressant-like effects of oleoylethanolamide in a mouse model of chronic 
      unpredictable mild stress.
PG  - 146-54
LID - S0091-3057(15)00118-5 [pii]
LID - 10.1016/j.pbb.2015.04.001 [doi]
AB  - Oleoylethanolamide (OEA) is an endocannabinoid analog that belongs to a family of 
      endogenous acylethanolamides. Increasing evidence suggests that OEA may act as an 
      endogenous neuroprotective factor and participate in the control of mental 
      disorder-related behaviors. In this study, we examined whether OEA is effective 
      against depression and investigated the role of circulating endogenous 
      acylethanolamides during stress. Mice were subjected to 28days of chronic 
      unpredictable mild stress (CUMS), and during the last 21days, treated with oral 
      OEA (1.5-6mg/kg) or 6mg/kg fluoxetine. Sucrose preference and open field test 
      activity were used to evaluate depression-like behaviors during CUMS and after 
      OEA treatment. Weights of the prefrontal cortex and hippocampus were determined, 
      and the adrenal index was measured. Furthermore, changes in serum 
      adrenocorticotropic hormone (ACTH), corticosterone (CORT) and total antioxidant 
      capacity (T-AOC), brain-derived neurotrophic factor (BDNF), and lipid 
      peroxidation product malondialdehyde (MDA) levels, and superoxide dismutase (SOD) 
      activities in the hippocampus and prefrontal cortex were detected. Our findings 
      indicate that OEA normalized sucrose preferences, locomotion distances, rearing 
      frequencies, prefrontal cortex and hippocampal atrophy, and adrenal indices. In 
      addition, OEA reversed the abnormalities of BDNF and MDA levels and SOD 
      activities in the hippocampus and prefrontal cortex, as well as changes in serum 
      levels of ACTH, CORT, and T-AOC. The antidepressant effects of OEA may be related 
      to the regulation of BDNF levels in the hippocampus and prefrontal cortex, 
      antioxidant defenses, and normalizing hyperactivity in the 
      hypothalamic-pituitary-adrenal axis (HPA).
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Jin, Peng
AU  - Jin P
AD  - Key Laboratory of Natural Resources and Functional Molecules of the Changbai 
      Mountain, Affiliated Ministry of Education, Yanbian University College of 
      Pharmacy, Yanji 133000, PR China; Department of Pharmacology, Ischemic/Hypoxic 
      Disease Institute, Cancer Research Institute, College of Medicine, Seoul National 
      University, Yongon-dong 28, Chongno-gu, Seoul 110-799, Republic of Korea; 
      Department of Biomedical Science, Ischemic/Hypoxic Disease Institute, Cancer 
      Research Institute, College of Medicine, Seoul National University, Yongon-dong 
      28, Chongno-gu, Seoul 110-799, Republic of Korea.
FAU - Yu, Hai-Ling
AU  - Yu HL
AD  - College of Medicine, Yanbian University, Park Street 977, Yanji, 133002 Jilin, PR 
      China. Electronic address: hlyu@ybu.edu.cn.
FAU - Tian-Lan
AU  - Tian-Lan
AD  - College of Medicine, Yanbian University, Park Street 977, Yanji, 133002 Jilin, PR 
      China.
FAU - Zhang, Feng
AU  - Zhang F
AD  - College of Medicine, Yanbian University, Park Street 977, Yanji, 133002 Jilin, PR 
      China.
FAU - Quan, Zhe-Shan
AU  - Quan ZS
AD  - Key Laboratory of Natural Resources and Functional Molecules of the Changbai 
      Mountain, Affiliated Ministry of Education, Yanbian University College of 
      Pharmacy, Yanji 133000, PR China. Electronic address: zsquan@ybu.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150410
PL  - United States
TA  - Pharmacol Biochem Behav
JT  - Pharmacology, biochemistry, and behavior
JID - 0367050
RN  - 0 (Antidepressive Agents)
RN  - 0 (Antioxidants)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Endocannabinoids)
RN  - 0 (Oleic Acids)
RN  - 01K63SUP8D (Fluoxetine)
RN  - 1HI5J9N8E6 (oleoylethanolamide)
RN  - 4Y8F71G49Q (Malondialdehyde)
RN  - 9002-60-2 (Adrenocorticotropic Hormone)
RN  - EC 1.15.1.1 (Superoxide Dismutase)
RN  - W980KJ009P (Corticosterone)
SB  - IM
MH  - Adrenocorticotropic Hormone/blood
MH  - Animals
MH  - Antidepressive Agents/*pharmacology/therapeutic use
MH  - Antioxidants/metabolism
MH  - Atrophy/drug therapy
MH  - Brain-Derived Neurotrophic Factor/metabolism
MH  - Corticosterone/blood
MH  - Depression/blood/complications/*drug therapy/metabolism
MH  - Disease Models, Animal
MH  - Endocannabinoids/*pharmacology/*therapeutic use
MH  - Fluoxetine/pharmacology/therapeutic use
MH  - Hippocampus/drug effects/metabolism/pathology
MH  - Male
MH  - Malondialdehyde/metabolism
MH  - Mice
MH  - Motor Activity/drug effects
MH  - Oleic Acids/*pharmacology/*therapeutic use
MH  - Prefrontal Cortex/drug effects/metabolism/pathology
MH  - Stress, Psychological/blood/complications/*drug therapy/metabolism
MH  - Superoxide Dismutase/metabolism
OTO - NOTNLM
OT  - Antidepressant
OT  - Brain-derived neurotrophic factor
OT  - HPA
OT  - Mice
OT  - Oleoylethanolamide
OT  - Oxidative stress
EDAT- 2015/04/14 06:00
MHDA- 2016/03/05 06:00
CRDT- 2015/04/14 06:00
PHST- 2015/01/07 00:00 [received]
PHST- 2015/03/30 00:00 [revised]
PHST- 2015/04/03 00:00 [accepted]
PHST- 2015/04/14 06:00 [entrez]
PHST- 2015/04/14 06:00 [pubmed]
PHST- 2016/03/05 06:00 [medline]
AID - S0091-3057(15)00118-5 [pii]
AID - 10.1016/j.pbb.2015.04.001 [doi]
PST - ppublish
SO  - Pharmacol Biochem Behav. 2015 Jun;133:146-54. doi: 10.1016/j.pbb.2015.04.001. 
      Epub 2015 Apr 10.